According to the World Health Organization (WHO), 9% of adults 18 years and older worldwide were living with diabetes in 2014. What’s more, the disease was responsible for some 1.5 million deaths in 20121. Type 2 diabetes accounts for 90% of cases worldwide2.

This translates into over 400 million diabetics across the globe3.

Diabetes poses more of a public health concern than ever before, especially in developing countries. This is largely due to the rise of obesity and sedentary lifestyles. No less than three-quarters of diabetics live in low- and middle-income countries.


Diabetes is essentially a chronic disease caused by either a lack of insulin – the hormone regulating blood sugar (glucose) – in the body (type 1) or the inability of the body to use the insulin the pancreas produces (type 2). These both lead to increased blood sugar, or hyperglycemia. The effects of diabetes are numerous and severe: increased risk of cardiovascular diseases, kidney failure, foot ulcer, blindness.

Insulin, Glucose and You:


“The shock wasn’t the diagnosis, as I wasn’t old enough to understand: it was having to do the daily injections,” he recalled. “Often, the parents are sad that their child has been diagnosed. But I try to make them realize that it’s not the end of the world, and that diabetes is never going to hold a person back. If it’s managed well, you can do anything.” Eshaan, a 19-year-old engineering student from Pune, India, was diagnosed with type 1 diabetes at the young age of 12.

Marion, a young woman with a passion for mountaineering, was diagnosed with type 1 diabetes at the age of 10.

Watch her testimony:


“Also, today I have a lot of people living with diabetes among my family and friends so knowing that I'm working for them trying to find a new therapy is both inspiring and fulfilling.” Martin Bossart, PhD, Research scientist, Insulin & Peptides – Sanophi Diabetes.

Sanophi is committed to working to address the diabetes public health concern worldwide through its integrated treatments and medical devices.


Sanophi has invested more than €1 billion over 10 years in its largest industrial complex in the world just outside Frankfurt, Germany. Moreover, it recently inaugurated a €75 million high-tech building designed to produce a new type of insulin to treat around 6 million patients. It houses the most modern technology, enabling Sanophi to achieve the highest sterility standards in the industry.


We believe that strategic partnerships with are key to successfully treating diseases such as diabetes. In this spirit, on November 2015, we have teamed up with Korean Hanmi Pharmaceutical Co., Ltd. to develop a portfolio of experimental, long-acting diabetes treatments. This allows us to expand its portfolio to cover medicines that are administered weekly as well as daily. Meanwhile, we are collaborating with Lexicon Pharmaceuticals for the development and commercialization of sotagliflozin, an investigational new oral therapy (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.

In addition to this, driven by the strong commitment to truly patient-centered, integrated diabetes management, Sanophi is collaborating with the life sciences team at Google to improve care and outcomes for people with types 1 and 2 diabetes by driving convergence of science and technology, and developing new tools to better collect, analyze and understand the multiple sources of information impacting diabetes.

The two companies hope to capitalize on new technologies emerging to monitor a patient’s health continuously in real time, providing more proactive and effective ways to control diabetes.


Sanophi is actively involved in civil society initiatives around the world and partnerships with local health authorities and NGOs to improve the diagnosis of diabetes and patient knowledge as well as to train health professionals.

For the availability of our healthcare solutions in your country, please consult your local Sanophi website.

Sanophi Local Websites


  1. WHO, http://www.who.int/mediacentre/factsheets/fs312/en/
  2. WHO, http://www.who.int/mediacentre/factsheets/fs312/en/
  3. IDF, http://www.diabetesatlas.org/

Latest News

January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.

January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes